Ergoteles LLC Cyma Bay Therapeutics, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$3.22 - $6.27 $580,124 - $1.13 Million	-180,163 Reduced 63.4%	103,997 $652,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $349,684 - $536,520	-126,240 Reduced 30.76%	284,160 $995,000
Q2 2022 Aug 12, 2022	BUY	$1.72 - $3.39 $705,888 - $1.39 Million	410,400 New	410,400 $1.21 Million
Q1 2021 May 12, 2021	SELL	$4.23 - $6.55 $416,232 - $644,520	-98,400 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$5.73 - $9.03 $563,832 - $888,551	98,400 New	98,400 $565,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.